ALKEM LABORATORIES
|
ALKEM LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 181.14 | 150.21 | 82.32 | 137.65 | 132.58 |
| CEPS(Rs) | 215.24 | 176.56 | 110.18 | 165.98 | 158.29 |
| DPS(Rs) | 45.00 | 40.00 | 50.00 | 34.00 | 30.00 |
| Book NAV/Share(Rs) | 999.47 | 860.94 | 756.56 | 722.48 | 616.95 |
| Tax Rate(%) | 12.31 | 10.46 | 22.84 | 8.89 | 12.18 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 13.01 | 11.58 | 8.97 | 13.44 | 14.82 |
| EBIT Margin(%) | 13.72 | 11.02 | 7.87 | 12.42 | 14.50 |
| Pre Tax Margin(%) | 13.09 | 10.44 | 7.27 | 12.07 | 14.05 |
| PAT Margin (%) | 11.48 | 9.35 | 5.61 | 11.00 | 12.34 |
| Cash Profit Margin (%) | 13.33 | 10.89 | 7.34 | 12.99 | 14.43 |
| Performance Ratios | |||||
| ROA(%) | 14.77 | 13.66 | 7.99 | 14.50 | 16.66 |
| ROE(%) | 19.93 | 18.74 | 11.39 | 20.99 | 23.91 |
| ROCE(%) | 21.56 | 19.52 | 13.09 | 18.69 | 22.56 |
| Asset Turnover(x) | 1.29 | 1.46 | 1.42 | 1.32 | 1.35 |
| Sales/Fixed Asset(x) | 4.17 | 4.51 | 4.36 | 3.86 | 3.58 |
| Working Capital/Sales(x) | 2.82 | 3.02 | 3.66 | 4.21 | 3.95 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.24 | 0.22 | 0.23 | 0.26 | 0.28 |
| Receivable days | 44.62 | 41.28 | 40.86 | 41.72 | 45.33 |
| Inventory Days | 52.79 | 49.60 | 57.10 | 63.54 | 57.51 |
| Payable days | 158.86 | 122.87 | 97.40 | 114.79 | 118.18 |
| Valuation Parameters | |||||
| PER(x) | 26.94 | 32.89 | 41.27 | 26.28 | 20.91 |
| PCE(x) | 22.67 | 27.98 | 30.84 | 21.79 | 17.51 |
| Price/Book(x) | 4.88 | 5.74 | 4.49 | 5.01 | 4.49 |
| Yield(%) | 0.92 | 0.81 | 1.47 | 0.94 | 1.08 |
| EV/Net Sales(x) | 4.46 | 4.63 | 3.39 | 4.07 | 3.71 |
| EV/Core EBITDA(x) | 19.24 | 22.96 | 21.53 | 19.52 | 15.10 |
| EV/EBIT(x) | 21.84 | 27.48 | 27.84 | 22.80 | 17.28 |
| EV/CE(x) | 4.43 | 5.09 | 3.80 | 3.39 | 3.16 |
| M Cap / Sales | 4.50 | 4.66 | 3.50 | 4.07 | 3.74 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 2.34 | 9.21 | 9.08 | 19.96 | 6.24 |
| Core EBITDA Growth(%) | 17.59 | 40.03 | -17.60 | 1.84 | 37.90 |
| EBIT Growth(%) | 24.03 | 51.23 | -25.55 | -0.23 | 43.49 |
| PAT Growth(%) | 22.33 | 79.92 | -40.08 | 3.87 | 40.76 |
| EPS Growth(%) | 20.59 | 82.47 | -40.19 | 3.82 | 40.63 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.09 | 0.12 | 0.14 | 0.30 | 0.23 |
| Current Ratio(x) | 2.73 | 2.61 | 2.32 | 1.76 | 1.92 |
| Quick Ratio(x) | 1.99 | 1.94 | 1.62 | 1.13 | 1.28 |
| Interest Cover(x) | 21.76 | 19.00 | 13.15 | 36.22 | 32.26 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.03 | 0.06 | 0.05 |
Compare Financial Ratios of peers of ALKEM LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ALKEM LABORATORIES | ₹67,351.5 Cr | 0.6% | -1.6% | 3.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹430,513.0 Cr | -0.1% | 3.4% | -0.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹170,614.0 Cr | 1.6% | -2.5% | 8.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹128,245.0 Cr | 0.8% | -0.9% | 13.5% | Stock Analytics | |
| CIPLA | ₹122,555.0 Cr | 1.3% | -0.6% | 3.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,803.0 Cr | 1% | 3.7% | 2.7% | Stock Analytics | |
ALKEM LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | 0.6% |
-1.6% |
3.1% |
| SENSEX | -0.5% |
1% |
4.6% |
You may also like the below Video Courses
